Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available - Practical Dose Selection Considerations and Real-World Access Challenges [0.03%]
太阳替尼治疗EGFR 20号外显子插入突变NSCLC：已获批但不可及-实用剂量选择考量和真实世界可及性挑战
Kim Abbegail Tan Aldecoa,Zhaohui Liao Arter,Sai-Hong Ignatius Ou et al.
Kim Abbegail Tan Aldecoa et al.
Sunvozertinib has emerged as one of the most promising tyrosine kinase inhibitors (TKIs) for previously treated non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (exon20ins) mutations, a ...
Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case Report [0.03%]
塞普替尼治疗获得性新型RET p.L730_G731insL继发耐药CCDC6-RET突变肺腺癌的疗效：个案研究报告
Chunyu Tian,Yang Zou,Jinxin Liu et al.
Chunyu Tian et al.
RET fusion is one of the key driver oncogenes in lung cancer. Selective RET inhibitors have become the standard of care for these patients. However, acquired resistance remains inevitable Among the mechanisms of on-target resistance, solven...
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib - A Case Report [0.03%]
克唑替尼获得性耐药后赫赛汀联合T-DM1和pyrotinib治疗病例一例报告
Misako Nagasaka,Zhaohui L Arter,Cathleen J Park et al.
Misako Nagasaka et al.
Trastuzumab deruxtecan, zongertinib and sevabertinib have been approved in the United States for the treatment of patients with advanced metastatic HER2 mutated non-small-cell lung cancer (NSCLC). Unfortunately, tumor progression is inevita...
Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung Cancer [0.03%]
基于NGS的MET扩增评估的基因拷贝数截断值探索性研究及其与非小细胞肺癌患者MET抑制剂疗效的相关性分析
Si-Yang Maggie Liu,Zhi Xie,Lixu Yan et al.
Si-Yang Maggie Liu et al.
Introduction: MET amplification is a critical oncogenic driver and a major mechanism of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC)....
Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients [0.03%]
预测非小细胞肺癌化疗疗效及生存结局的免疫血清标志物灵敏度和特异度研究
Putthapoom Lumjiaktase,Nanthisa Kemawichanurat,Kanthon Santiwiwas et al.
Putthapoom Lumjiaktase et al.
Purpose: Chemotherapy is the main therapy for non-targetable advanced non-small cell lung cancer (NSCLC). Nevertheless, few biomarkers are currently available for predicting clinical outcomes and monitoring treatment resp...
Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in China [0.03%]
对中国EGFR突变阳性晚期非小细胞肺癌患者一线使用阿法替尼治疗的前瞻性、观察性、真实世界研究
Jianying Zhou,Yongsheng Wang,Jiewen Peng et al.
Jianying Zhou et al.
Purpose: Approximately 38% of Chinese patients with non-small cell lung cancer (NSCLC) exhibit a mutation in the epidermal growth factor receptor (EGFR) gene. Afatinib, which targets the EGFR, is approved for first-line t...
Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung Cancer [0.03%]
Claudin-3低表达与非小细胞肺癌不良预后相关
Nina Schraps,Martin Reck,Birgit Hantzsch-Kuhn et al.
Nina Schraps et al.
Background: Claudin 3 (CLDN3) is a transmembrane protein which forms tight junctions (TJs) together with other claudins, occludin, and junctional adhesion molecules. Because of its membranous localization CLDN3 is a poten...
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report [0.03%]
索拉非尼致手足皮肤反应的溻渍疗法护理报告
Alexandria T M Lee,Cathleen June Park,Zhaohui Liao Arter et al.
Alexandria T M Lee et al.
Alectinib is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that has been widely used as first-line (1L) treatment of advanced ALK+ non-small cell lung cancer (NSCLC) ever since its approved indication ...
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC - Insights From Genomics, Proteomics, and Metabolomics [0.03%]
基于基因组学、蛋白质组学和代谢组学的非小细胞肺癌免疫检查点抑制剂反应预测的整合多组学方法见解
Eman Elayeh,Shereen M Aleidi,Orwa Aboud et al.
Eman Elayeh et al.
Background and purpose: Immune checkpoint inhibitors (ICIs) have improved outcomes in non-small cell lung cancer (NSCLC), yet durable benefit is limited to a subset of patients. Reliable predictive biomarkers are therefor...
Pulmonary Nodular Lymphoid Hyperplasia: Reviewing a Lung Cancer Mimicker [0.03%]
肺结节样淋巴组织增生症：一种肺癌的鉴別诊断疾病文献复习
Gabriela Schneider Galvão,Jônatas Fávero Prietto Dos Santos,Ying-Han R Hsu et al.
Gabriela Schneider Galvão et al.
Background: Pulmonary nodular lymphoid hyperplasia is a rare benign lymphoproliferative disorder. Patients are commonly asymptomatic. Its radiological presentation is characterized by peripheral single nodular lesion, mul...